Investors' Soapbox AM

A Key Asset for Lilly, Incyte

Incremental data shared Monday at the meeting of the American College of Rheumatology helped provide definition for key assets in Lilly's autoimmune portfolio. Robust patient-reported-measures data on baricitinib continue to build excitement over its profile, while high rates of infection are likely to keep expectations on tabalumab muted.